A new generation where science, nature, and technology merge...
KRTL Biotech is an international research and development company with operations in the US, Korea, and Canada, with a consortium of experienced Korean, Canadian, and US doctors and researchers dedicated to improving mankind’s debilitating physical and mental ailments with progressive pre-formulations created by our organization. Their disciplines are in the CBD and Psilocybin arena and will study and work with these and other plant-based products.
We are a biotech company instituting a facet of studies, with pharmaceutical-grade resources and technologies that will help synthesize our research to help expedite our goals. Our scientists are leaders in cancer and neurology research, with over 80 years of experience in the research industry.
KRTL Biotech Inc. now has obtained a Ministry of Food and Drug Safety (MFDS), formerly known as the Korea Food & Drug Administration (KFDA) approval, and our team can commence research between psilocybin and CBD that will better assist the medical and psychological community in the treatment of specific disorders, which include but not limited to pain resulting from Cancer treatment, Autism, PTSD, ADHD, Depression, Addiction, improvement in concentration and other psychological illnesses.
KRTL Biotech has partnered with a multitude of universities and biotech companies to facilitate this venture. Through our strategic alliances with professionals in other industries such as marketing, manufacturing, cultivation, distribution, public markets, and corporate structure, we hold an advantage in comparison to other research and development companies because we understand the complete evolution of the product, from concept to a marketable item generating revenue.
These relationships have created opportunities. For example, we have signed an exclusive manufacturing agreement with an FDA class 2 approved CGMP manufacturer in Korea, named C3 Co. Ltd. Another agreement we have reached is with JBF Jeonnam Bioindustry Foundation Center of Natural Resources Research. They have signed with KRTL Asia, KRTL Biotech, and KRTL Canada. With JBF we can now add over 20 additional ailments and include veterinary medicines to our roster of research. In addition, this allows the KRTL group access to local grant opportunities. Another is Korea Distribution Industry Promotion Agency, a non-profit organization that is under the Ministry of Trade and the Korean Central Government of Energy, signs agreement with KRTL Asia. This organization collaborates with the distribution industry with both import and international export.
Our board and partners have experience with collaboration agreements, licensing agreements, and creating equity arrangements. These are some areas that will create opportunities for the right entity ready to get involved.
We are eager to embark on this journey by uniting minds and developing groundbreaking answers to these areas, where science can truly shine.